ReviewMolecular biology reports2026
Molecular mechanisms of programmed cell death in aortic dissection and advances in clinical translation.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aortic dissection (AD) is an acute cardiovascular emergency characterized by rapid progression and an extremely high risk of mortality. Its fundamental pathological process begins with an intimal tear, through which blood enters the medial layer to form a false lumen, leading to structural destabilization of the aortic wall, impaired organ perfusion, and an increased risk of rupture. In recent years, with the continued advancement of multi-omics sequencing technologies, the initiation and progression of AD have no longer been regarded merely as a consequence of hemodynamic injury. Instead, AD is now recognized as a complex pathological process driven by vascular smooth muscle cell (VSMC) loss, phenotypic remodeling, extracellular matrix (ECM) degradation, inflammatory amplification, and redox imbalance. Within this framework, programmed cell death (PCD) has emerged as a pivotal molecular hub linking structural destruction to intracellular dysregulation. Accumulating evidence indicates that multiple forms of PCD are involved in AD progression and interact with oxidative stress, mitochondrial dysfunction, immune cell infiltration, and matrix metalloproteinase activation to form a mutually reinforcing injury network. At present, the clinical management of AD still centers on rapid imaging-based diagnosisand timely standardized intervention, including intensive blood pressure and heart rate control, open surgical repair, and endovascular repair. Although substantial progress has been made in elucidating the mechanisms of PCD, clinical translational evidence for precision therapies targeting specific cell death pathways remains limited. Therefore, this review summarizes the mechanistic roles of PCD in AD and integrates these insights with emerging strategies for early diagnosis and precision treatment.
Indexed as
Identifiers
42720823What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.